Jin Wei, Wang Xin, Wang Jie, Lin Lin
Department of Chinese Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Front Oncol. 2022 Feb 28;12:820408. doi: 10.3389/fonc.2022.820408. eCollection 2022.
Epidermal growth factor receptor (EGFR) mutations have a low incidence in squamous cell lung cancer (SqCLC), and the clinical efficacy of EGFR tyrosine kinase inhibitors (TKIs) in -mutated SqCLC is far less than that in -mutated lung adenocarcinoma. The treatment strategy for patients with mutated non-small cell lung cancer who are refractory to EGFR TKIs has become a current dilemma and challenge.
A case of a 69-year-old male patient suffering from intermittent cough and hemoptysis was diagnosed with -mutated advanced SqCLC (stage cT2bN2M1). The patient was treated with camrelizumab alone after five courses of different systemic therapies and achieved a partial response, with an eminent progression-free survival of more than 24 months. Grade 1 to 2 reactive cutaneous capillary endothelial proliferation and mild pruritus were observed during the treatment. No other immune-related adverse events were observed.
Monotherapy of immune-checkpoint inhibitors may be considered as a later-line option for -mutated advanced SqCLC patients with PD-L1 expression.
表皮生长因子受体（EGFR）突变在肺鳞状细胞癌（SqCLC）中的发生率较低，EGFR酪氨酸激酶抑制剂（TKIs）在突变型SqCLC中的临床疗效远低于在突变型肺腺癌中的疗效。对EGFR TKIs耐药的突变型非小细胞肺癌患者的治疗策略已成为当前的困境和挑战。
一名69岁男性患者，有间歇性咳嗽和咯血症状，被诊断为突变型晚期SqCLC（cT2bN2M1期）。该患者在接受五个疗程的不同全身治疗后单独使用卡瑞利珠单抗治疗，获得部分缓解，无进展生存期显著超过24个月。治疗期间观察到1至2级反应性皮肤毛细血管内皮增生和轻度瘙痒。未观察到其他免疫相关不良事件。
免疫检查点抑制剂单药治疗可被视为PD-L1表达的突变型晚期SqCLC患者的后线治疗选择。
